An Investigator Sponsored Phase 1a/1b Trial of Selinexor in Combination With Irinotecan in Patients With Adenocarcinoma of Stomach and Distal Esophagus
Latest Information Update: 30 Jan 2016
Price :
$35 *
At a glance
- Drugs Selinexor (Primary) ; Irinotecan
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 14 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 07 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 08 Nov 2014 New trial record